NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on Soleno Therapeutics, Inc. (NASDAQ: SLNO), a company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, is currently being evaluated in a Phase III clinical development program.
The share price of SLNO experienced a (+98%) surge with strong volumes on 15th March 2019 after it announced that the Data Safety Monitoring Board (DSMB) had recommended the continuation of the Company's Phase III trial in Prader-Willi Syndrome (PWS) patients, DESTINY PWS, without any changes.
Complimentary analyst report on SLNO READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/slno/
Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel titled, "How Will Orphan & Ultra-Orphan Drugs Stand up Against Pricing Uncertainties?", and provide a corporate update, at the 31st Annual ROTH Conference, taking place March 17-19, 2019, in Dana Point, CA.
Dr. Bhatnagar will also present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20, 2019, in New York, NY. The presentation will take place on Wednesday, March 20.
Company review, recent corporate highlights and more in this full report READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/slno/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source